These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 25003492)

  • 1. Clinical trial design for phase 1 studies of drug combinations.
    Paller C
    Clin Adv Hematol Oncol; 2014 May; 12(5):335-7. PubMed ID: 25003492
    [No Abstract]   [Full Text] [Related]  

  • 2. [A combination phase I/II study--dose escalation plan].
    Yamamoto N
    Gan To Kagaku Ryoho; 2000 Dec; 27(14):2267-74. PubMed ID: 11142175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A non-parametric approach to the design and analysis of two-dimensional dose-finding trials.
    Ivanova A; Wang K
    Stat Med; 2004 Jun; 23(12):1861-70. PubMed ID: 15195320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adaptive design may hasten clinical trials.
    Schmidt C
    J Natl Cancer Inst; 2007 Jan; 99(2):108-9. PubMed ID: 17227993
    [No Abstract]   [Full Text] [Related]  

  • 5. [Phase I clinical trial design of anticancer agents--a Fibonacci and a modified Fibonacci sequence].
    Kusaba H; Tamura T
    Gan To Kagaku Ryoho; 2000 May; 27(5):775-8. PubMed ID: 10832451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current issues in phase I trials: new study designs and informed consent procedures.
    Cavalli F; Sessa C
    Ann Oncol; 1999; 10 Suppl 6():147-8. PubMed ID: 10676566
    [No Abstract]   [Full Text] [Related]  

  • 7. Commentary on 'Small-sample behavior of novel phase I cancer trial designs'.
    Cheung YK
    Clin Trials; 2013 Feb; 10(1):86-7; discussion 88-92. PubMed ID: 23345306
    [No Abstract]   [Full Text] [Related]  

  • 8. Discussion of 'small-sample behavior of novel phase I cancer trial designs' by Assaf P Oron and Peter D Hoff.
    Carlin BP; Zhong W; Koopmeiners JS
    Clin Trials; 2013 Feb; 10(1):81-5; discussion 88-92. PubMed ID: 23345305
    [No Abstract]   [Full Text] [Related]  

  • 9. Dose selection in phase I studies: why we should always go for the most effective.
    Haines IE
    J Clin Oncol; 2008 Jul; 26(21):3650-2; author reply 3652-3. PubMed ID: 18640947
    [No Abstract]   [Full Text] [Related]  

  • 10. Dose selection in phase I studies: why we should always go for the top.
    Sleijfer S; Wiemer E
    J Clin Oncol; 2008 Apr; 26(10):1576-8. PubMed ID: 18332465
    [No Abstract]   [Full Text] [Related]  

  • 11. Choice of designs and doses for early phase trials.
    Zhou Y
    Fundam Clin Pharmacol; 2004 Jun; 18(3):373-8. PubMed ID: 15147290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Building firm foundations for therapy development.
    Dignam JJ; Karrison TG
    J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25710961
    [No Abstract]   [Full Text] [Related]  

  • 13. Practical modifications of the continual reassessment method for phase I cancer clinical trials.
    Faries D
    J Biopharm Stat; 1994 Jul; 4(2):147-64. PubMed ID: 7951271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re: Dose escalation methods in phase I cancer clinical trials.
    Zohar S; O'Quigley J
    J Natl Cancer Inst; 2009 Dec; 101(24):1732-3; author reply 1733-5. PubMed ID: 19893006
    [No Abstract]   [Full Text] [Related]  

  • 15. Practical designs for Phase I combination studies in oncology.
    Wages NA; Ivanova A; Marchenko O
    J Biopharm Stat; 2016; 26(1):150-66. PubMed ID: 26379085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The changing landscape of phase I trials in oncology.
    Wong KM; Capasso A; Eckhardt SG
    Am Soc Clin Oncol Educ Book; 2015; ():3-8. PubMed ID: 25993134
    [No Abstract]   [Full Text] [Related]  

  • 17. Should We Preclude Phase 1 Clinical Trials From Enrolling Elderly Individuals?
    Balducci L
    Cancer Control; 2015 Apr; 22(2):232-4. PubMed ID: 26068770
    [No Abstract]   [Full Text] [Related]  

  • 18. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics.
    LoRusso PM; Boerner SA; Seymour L
    Clin Cancer Res; 2010 Mar; 16(6):1710-8. PubMed ID: 20215546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ethical and Policy Issues for Seamless Phase I Oncology Trials.
    Hutchinson N; Vinarov E; Iasonos A; Kimmelman J
    J Clin Oncol; 2020 Mar; 38(7):669-673. PubMed ID: 31877086
    [No Abstract]   [Full Text] [Related]  

  • 20. Dose finding with continuous outcome in phase I oncology trials.
    Wang Y; Ivanova A
    Pharm Stat; 2015; 14(2):102-7. PubMed ID: 25408518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.